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Abstract Collagen and the cross-linked collagen-related pep-
tide (CRP-XL) each induced platelet p38 mitogen-activated pro-
tein kinase (p38) phosphorylation after 2 min. Subsequent de-
phosphorylation occurred in platelets activated with collagen,
but not with CRP-XL, demonstrating glycoprotein VI-indepen-
dent regulation of p38. Okadaic acid and fostriecin, inhibitors
speci¢c for protein phosphatase 2A (PP2A), blocked p38 de-
phosphorylation, and PP2A co-immunoprecipitated with phos-
pho-p38. In addition, use of phenylarsine oxide suggested that
tyrosine phosphatases and PP2A may act in concert to dephos-
phorylate p38. Finally, regulation of p38 in collagen-stimulated
Glanzmann’s platelets was indistinguishable from that in normal
platelets, showing that p38 regulation is independent of integrin
KIIbL3. 0 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The activation of platelets by collagen leads both to their
aggregation and to procoagulant expression, the two branches
of the hemostatic pathway. During the activation process pro-
tein kinases become activated and cytoskeletal changes occur
which lead to ¢lopodial extension and to spreading of adher-
ent platelets. Inhibition of p38 mitogen-activated protein ki-
nase (MAPK) has been shown to attenuate collagen-stimu-
lated platelet aggregation [1] and to impair the blebbing of
platelets, which may be an important step in their procoagu-
lant response [2].
p38 is a member of the MAPK superfamily and four iso-
forms (K, L, Q and N) of the p38 MAPK subfamily exist. The K
isoform is commonly referred to as p38 [3,4]. All four species
have been detected in platelets [5], where collagen is reported
to activate exclusively the K and L forms. In other cells, p38
MAPK is activated by dual phosphorylation of its TGY motif
[6,7], by its upstream activators, the MAPK kinases, MKK3
and MKK6 [8,9]. These proteins are yet to be detected in
platelets.
The p38 MAPK family members have been categorized as
stress-activated protein kinases, which respond to numerous
cytokines and to environmental and chemical stress [8], lead-
ing to cellular responses such as in£ammation and apoptosis.
Activation of p38 leads to subsequent activation of MAPK-
activated protein kinases 2 and 3 and, in turn, to the phos-
phorylation of small heat shock protein 27 (HSP27), involved
in actin remodeling. This suggests that p38 may play an im-
portant role in cytoskeletal reorganization in platelets as well
as in other cells [10^12].
We have previously shown that platelet p38 MAPK is acti-
vated by collagen, CRP-XL (cross-linked collagen-related
peptide) and a thromboxane analogue [1]. Indirectly, others
have shown p38 MAPK activation by K-thrombin and its
involvement in the phosphorylation of cytosolic phospholi-
pase A2 (cPLA2), although reports on the e¡ect of p38 on
cPLA2 activity have been con£icting [13^15].
Research into platelet protein phosphorylation has mainly
concentrated on the action of protein kinases. In contrast, the
role of protein phosphatases, which mediate dephosphoryla-
tion, remains poorly understood. The present study examines
the role of protein phosphatases as negative regulators of p38
MAPK. Protein phosphatase 2A (PP2A) is a type II serine/
threonine phosphatase consisting of a 36 kDa catalytic sub-
unit and two regulatory subunits [16]. Type II protein phos-
phatases are able to dephosphorylate p38 MAPK: PP2A de-
phosphorylates p38 in vitro [17], and PP2C has previously
been described as a regulator of p38 activity in vivo [18].
Following its recruitment to the cytoskeleton after platelet
aggregation, PP2A may play a role in dephosphorylating cy-
toskeletal proteins [19] and in microtubule rearrangement [20].
Using okadaic acid (OA), a well-established and potent inhib-
itor of PP2A [21,22], and other selective inhibitors, we inves-
tigated the involvement of PP2A in the regulation of p38 in
platelets stimulated by collagen and CRP-XL. By immunopre-
cipitation of p38 we have shown a direct association between
p38 and PP2A.
Platelets contain several protein tyrosine phosphatases
(PTPases) and a recent report shows that glycoprotein VI
(GpVI) stimulation by collagen and CRP-XL leads to the
phosphorylation of PTP1C (also called SHP-1) [23]. The
present study indicates a role for a PTPase, which may
work together with PP2A to remove phosphate from both
the tyrosine and threonine residues within the p38 activation
motif, to maintain the enzyme in the predominantly non-
phosphorylated form in resting platelets.
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2. Materials and methods
2.1. Materials
Bovine tendon collagen type I ¢bers were a gift from Ethicon Inc.
(Somerville, NJ, USA) and were dialyzed against 0.01 M acetic acid.
CRP, GCO(GPO)10GCOG was synthesized and cross-linked as de-
scribed in [24]. GR144053F was a gift from Glaxo Wellcome (Steven-
age, UK). Rabbit polyclonal anti-phospho-p38 (Thr180/Tyr182) anti-
body (Ab), rabbit polyclonal Ab which recognizes both basal and
phospho-p38, and immobilized anti-phospho-p38 (Thr180/Tyr182)
monoclonal Ab (mAb) were from New England BioLabs (Hitchin,
UK). MAb directed against the catalytic subunit of PP2A was from
TCS Biologicals (Buckingham, UK). Rabbit antiserum SAK7, which
binds a p38 C-terminal peptide, i.e. both phospho- and basal p38
forms [1], was a gift from Prof. J. Saklatvala, Kennedy Institute,
London, UK. Control mouse IgG was from Autogen Bioclear (Calne,
UK). Phenylarsine oxide (PAO) and OA were from Calbiochem-
Novabiochem (Nottingham, UK). Fostriecin was from Alexis Corp.
(Nottingham, UK). Horseradish peroxidase-conjugated donkey anti-
rabbit Ig and sheep anti-mouse Ig were from Amersham Pharmacia
Biotech (Buckinghamshire, UK). All other reagents were from Sigma-
Aldrich (Dorset, UK).
2.2. Platelet preparation
Platelets, from concentrates supplied within 48 h of donation by the
National Blood Service (Cambridge, UK), were prepared by removing
red blood cells after centrifugation (250Ug, 15 min). Platelet-rich
plasma, with apyrase grade VII (0.25 U/ml), was spun (700Ug,
15 min) and washed with HEPES-bu¡ered saline (145 mM NaCl,
5 mM KCl, 10 mM glucose, 1 mM MgSO4, 0.5 mM EGTA, 10 mM
HEPES, pH 7.4) at 700Ug for 10 min prior to resuspension in this
bu¡er at 1U109 platelets/ml. Glanzmann’s type I platelets, from an
informed donor, were from the Department of Haematology, Royal
Hallamshire Hospital (She⁄eld, UK), and were prepared as above
from whole blood collected into acid citrate dextrose.
2.3. Platelet stimulation
Platelet suspensions (50 Wl) were incubated at 30‡C either with in-
creasing concentrations of collagen or CRP-XL for 3 min, or with
collagen (50 Wg/ml), CRP-XL (25 Wg/ml) or the vehicle control (0.01 M
acetic acid) for up to 480 s. Phosphatase inhibitors were dissolved in
dimethyl sulfoxide (DMSO) unless otherwise stated. OA (1 WM) and
PAO (2 WM) were added to platelets 10 min prior to introduction of
collagen. Antagonism of the integrin KIIbL3 was achieved by prein-
cubating platelets with GR144053F (2 WM) for 20 min before stimu-
lation with collagen or CRP-XL. Platelet activation was terminated by
addition of an equal volume of Laemmli’s bu¡er, and then samples
were boiled and subjected to sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE).
For blockade of phosphatase activity in vitro, platelets (5U108 in
500 Wl) were stimulated for 2 min with collagen and subsequently
lysed with 500 Wl of 2U extraction bu¡er (300 mM NaCl, 20 mM
Tris, 10 mM EDTA, 2% Triton X-100, 1 protease cocktail tablet/10 ml
(Boehringer Mannheim), pH 7.3). A 200 Wl aliquot of lysate was
removed and incubated with vehicle control (DMSO), fostriecin
(5 WM in H2O) or OA (1 WM), at 30‡C for 10 min and 30 min. A
40 Wl sample was mixed with 10 Wl of 5U Laemmli’s bu¡er, boiled
and subjected to SDS^PAGE.
2.4. Western blotting
Proteins were separated using 10% SDS gels and transferred onto
nitrocellulose in a Hoefer semi-dry blotter for 2 h at 0.8 mA/cm2. All
blots were checked for protein loading and evenness of transfer by
staining membranes with Ponceau (0.1% Ponceau, 5% acetic acid)
prior to blocking. Membranes were blocked with 5% milk (milk pow-
der in 1U Tris-bu¡ered saline Tween (TBST), 20 mM Tris, 140 mM
NaCl, 0.1% Tween-20, pH 7.6) for 30 min at room temperature. Anti-
phospho-p38 (Thr180/Tyr182) MAPK polyclonal antibody (diluted 1/
1000 in 5% bovine serum albumin (BSA)^TBST) was used to probe
the membranes at 4‡C overnight. Membranes were stripped as re-
quired in stripping bu¡er (62.5 mM Tris, 2% SDS, 100 mM L-mer-
captoethanol, pH 6.7) for 20 min at room temperature, washed ex-
tensively with TBST, blocked with 5% milk and re-probed with total
p38 MAPK antibody (1/1000 in 5% BSA^TBST) at 4‡C overnight.
Primary anti-phospho-p38 and anti-total p38 MAPK antibodies were
detected using an anti-rabbit secondary antibody diluted 1/10 000 in
1% BSA^TBST. Washed blots were subjected to enhanced chemilu-
minescence (ECL). Bands representing phospho-p38 MAPK were
quanti¢ed by video densitometry using a Leica Q550C image analyzer
and expressed as integrated optical density (IOD) [2]. Glanzmann’s
platelets were used only once due to the limited access to donors, so
the IOD of the band representing total p38 MAPK was used to
normalize the measurement of phospho-p38.
2.5. Immunoprecipitation of p38 MAPK
Platelets were stimulated with collagen (50 Wg/ml) for 2 min, and
lysed with 2U p38 lysis bu¡er (40 mM Tris, 300 mM NaCl, 2 mM
EDTA, 1 mM EGTA, 2% Triton X-100, 5 mM sodium pyrophos-
phate, 2 mM L-glycerophosphate, 2 mM Na3VO4, 10 Wg/ml leupeptin,
2 mM PMSF, pH 7.5). The Triton-insoluble pellet was removed and
the lysates were pre-cleared for 1 h at 4‡C using mouse IgG. Phospho-
p38 MAPK was immunoprecipitated at 4‡C overnight using an aga-
rose-immobilized mAb that binds the phosphorylated protein. Immu-
noprecipitates were washed three times in p38 lysis bu¡er (1U con-
centration) prior to elution of proteins with Laemmli’s bu¡er and
SDS^PAGE. After blocking the membrane with 3% milk for 30
min, PP2A was detected using a mAb (1 Wg/ml in milk) at 4‡C over-
night, followed by anti-mouse secondary antibody (1/2000 in milk).
As a control, agarose-immobilized anti-phospho-p38 Ab was sub-
jected to the immunoprecipitation (IP) protocol in the absence of
platelet proteins to allow Ab-derived bands to be detected. Mouse
IgG was also subjected to the IP protocol and captured using protein
A/G agarose beads. Proteins were also eluted from 30 Wl of beads
alone and run alongside IP samples. Phospho- and non-phosphory-
lated p38 MAPK were also immunoprecipitated using SAK7 (5 Wl)
from platelets stimulated for 0, 2 or 8 min with collagen (50 Wg/ml)
and then lysed. Lysates were pre-cleared for 1 h using rabbit IgG.
Protein A/G agarose beads were coated with antiserum for 2 h at 4‡C
and then mixed with platelet lysates for 5 h at 4‡C. The beads were
washed and proteins eluted as above.
2.6. Statistical analysis
Results shown are representatives of at least three experiments.
Means and S.E.M. are shown on graphs and the number of exper-
imental repeats indicated in the ¢gure legends. Linear regression anal-
ysis of the time course of collagen-induced and CRP-XL-induced p38
phosphorylation between 90 and 480 s was done using the InStat0
program.
3. Results
3.1. Collagen causes p38 dephosphorylation whereas CRP-XL
does not
Phosphorylation of p38 MAPK was examined using plate-
lets stimulated with either native type I collagen ¢brils or the
GpVI-speci¢c ligand, CRP-XL. Dose^response curves for p38
MAPK phosphorylation (Fig. 1A) indicated that maximal p38
phosphorylation was achieved using collagen at a dose of 25^
100 Wg/ml or CRP-XL at 25^50 Wg/ml, thus allowing saturat-
ing concentrations of ligands to be de¢ned. After a 30 s lag,
collagen (50 Wg/ml) caused an increase in p38 phosphoryla-
tion, which reached a peak between 90 and 120 s after acti-
vation and then continuously declined by 480 s as shown in
Fig. 1D. CRP-XL-induced (25 Wg/ml) p38 MAPK phosphor-
ylation also showed a 30 s delay, peaking between 90 and 240 s
and was maintained without decline for up to 480 s. Repre-
sentative Western blots for activation by collagen and CRP-
XL, respectively, are shown in Fig. 1B and C. The lower
panels in Fig. 1B and C indicate total p38 levels in each
lane and demonstrate that the decrease in p38 phosphoryla-
tion in the presence of collagen is not a result of protein
degradation. Regression analysis of p38 phosphorylation in
CRP-XL-stimulated platelets showed that peak activity did
not decline between 90 and 480 s (P=0.98). In separate ex-
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periments (not shown), there was no decrease in p38 phos-
phorylation levels even after 20 min exposure to CRP-XL. In
marked contrast, in collagen-treated platelets there was a sig-
ni¢cant, linear decline to about half peak levels of phosphor-
ylation by 480 s (P6 0.0006). These activation pro¢les suggest
that collagen regulates p38 activity in a di¡erent manner to
CRP-XL and that signals from collagen result in a more rapid
down-regulation of the phosphorylated state.
3.2. PP2A is responsible for the decline in p38 phosphorylation
Pretreatment of platelets for 20 min with 1 WM OA in-
creased the phosphorylation of p38 MAPK by at least
50 IOD units. Both the 30 s lag in p38 phosphorylation after
the addition of collagen and the decline subsequent to peak
p38 phosphorylation levels were abolished in the presence of
OA (Fig. 2A and B). OA is a more potent inhibitor of PP2A
(IC50w0.1 nM) than PP1 (IC50w10 nM) in vitro, but concen-
trations required for inhibition in vivo can be much higher,
requiring up to 1 WM for complete blockade of PP2A [25]. We
found that lower concentrations (10 nM and 100 nM) were
without e¡ect.
The inhibitor fostriecin has a high a⁄nity and speci¢city for
PP2A (IC50w3.2 nM) compared to PP1 (IC50w131 WM) [26].
It therefore allowed better discrimination of the serine/threo-
nine phosphatase causing the decline in p38 MAPK phos-
phorylation. Treatment of intact platelets with up to 1 WM
fostriecin had no e¡ect on basal or collagen-stimulated p38
phosphorylation and suggested that the compound was mem-
brane impermeant at the concentrations tested (data not
shown). To allow access of fostriecin to PP2A and to ensure
complete inhibition of the phosphatase, phospho-p38 levels
were measured in lysates from collagen-stimulated platelets
in the presence and absence of fostriecin (5 WM) or OA
Fig. 1. Collagen and CRP-XL cause an equivalent increase in p38
phosphorylation, but subsequent p38 dephosphorylation is mediated
by collagen only. A: Integrated optical density (IOD) plot for p38
phosphorylation in response to increasing doses of collagen (F) or
CRP-XL (R). Data from four similar experiments represent means
and S.E.M. Platelets in suspension were stimulated with 50 Wg/ml
collagen ¢bers (B) or 25 Wg/ml CRP-XL (C) for the indicated times.
Lower panels in B and C show total p38 levels in the same blots
after stripping and re-probing for p38 irrespective of its phosphory-
lation status. Phospho-p38 and total p38 were detected as detailed
in Section 2.4. D: IOD data for p38 phosphorylation with time
from ¢ve similar blots for collagen (F) and four similar blots for
CRP-XL (R). Data represent means and S.E.M.
Fig. 2. PP2A and a PTPase mediate platelet p38 dephosphorylation.
A: Platelets were preincubated with 1 WM OA for 10 min before ac-
tivation by collagen (50 Wg/ml) for the indicated times. B: Platelets
were activated with collagen (50 Wg/ml) for 2 min, lysed and incuba-
ted with vehicle control (DMSO), fostriecin (5 WM) or OA (1 WM)
for 10 min and 30 min. C: PTPase involvement is shown by prein-
cubation with 2 WM PAO for 10 min prior to activation with colla-
gen (50 Wg/ml) for the indicated times. These experiments were con-
ducted at least three times. Phospho-p38 levels were detected using
the immunodetection methods described in Section 2.4.
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(1 WM). Both inhibitors caused an accumulation of phospho-
p38, which was clearly evident after a 10 min or 30 min
incubation as seen in Fig. 2B. Finally, we used tautomycin,
an inhibitor shown to be more selective towards PP1 than
PP2A [27] and found that there was no e¡ect on p38 phos-
phorylation when it was employed at 1 WM (data not shown).
3.3. A PTPase dephosphorylates p38 MAPK
PAO has been shown to inhibit PTPase activity in platelets
[28] and was used to investigate the involvement of the latter
in p38 dephosphorylation. When PAO was employed in our
system at 2 WM, a substantial increase in p38 phosphorylation
was apparent (Fig. 2C). The high level of phospho-p38 seen
under basal conditions was retained throughout the time
course of activation by collagen.
3.4. PP2A directly interacts with p38 MAPK
The use of inhibitors suggested a functional role for PP2A
as a regulator of p38 MAPK. We therefore sought to dem-
onstrate a physical interaction between PP2A and p38 by
examining proteins, which co-precipitate with phospho-p38.
Platelets were stimulated with collagen for 2 min, at the
peak of p38 phosphorylation, and the MAPK was immuno-
precipitated with a phospho-p38-speci¢c mAb (Fig. 3A). The
isolated protein complexes were subjected to SDS^PAGE and
Western blotting as described in Section 2. Blots were probed
with a mAb raised against the 36 kDa catalytic subunit of
PP2A. Fig. 3A (lane 2) shows that phospho-p38 is pulled
down by the immunoprecipitating Ab. The presence of phos-
pho-p38 in the whole cell lysate from collagen-activated plate-
lets (lane 1) is also indicated and can be used to identify
phospho-p38 in the IP sample. The blot from the same experi-
ment was stripped and re-probed for PP2A. As seen in Fig.
3B, PP2A associated with p38 MAPK (lane 2), and the anti-
body control (lane 3) showed that the band that corresponded
to PP2A was not contamination from the immunoprecipitat-
ing antibody. The interaction of PP2A with p38 was speci¢c,
as mouse IgG did not precipitate the phosphatase (Fig. 3B,
lane 5). Present in all three panels of this ¢gure are a series of
dense bands, which migrate between approximately 27 and
34 kDa (Fig. 3A and B, lanes 4^5 and C, lanes 3^5). These
bands were proteins eluted from the protein A/G agarose
beads themselves, as deduced from lane 4 where beads not
subjected to the immunoprecipitation protocol were treated
with Laemmli’s bu¡er and boiled (Fig. 3A and B). These
proteins cross-reacted with the secondary antibodies to pro-
duce the dark bands. Further, Fig. 3C shows that when p38
was immunoprecipitated using SAK7, PP2A was much more
prominently detected in lysates of platelets stimulated for
2 min with collagen compared with those from platelets stimu-
lated for 0 or 8 min. This is consistent with an obligatory role
for PP2A in the dephosphorylation of p38. In contrast, im-
munoprecipitates of PP2A (not shown) contained no detect-
able p38. It is likely that this re£ects the small proportion of
PP2A that binds p38, given that a wide range of phosphopro-
teins will compete with p38 for PP2A activity.
3.5. KIIbL3 activation is not required for p38 phosphorylation
or its subsequent dephosphorylation in platelets
An essential role for platelet aggregation and the ¢brinogen
receptor, KIIbL3, has been described in the recruitment of
PP2A to the cytoskeleton, allowing PP2A to dephosphorylate
Fig. 3. PP2A directly associates with phospho-p38. A: Immunopre-
cipitation of phospho-p38 (P-p38) from collagen-stimulated platelets
using an agarose-immobilized monoclonal Ab followed by immuno-
detection of phosphorylated protein using a polyclonal Ab. Lane 1
shows whole cell lysate from platelets stimulated with collagen for
2 min (Wcl). Lane 2 depicts the IP sample (P-p38) and lane 3 shows
the phospho-p38 mAb control (Ab). Lane 4 demonstrates proteins
that are eluted from the protein A/G agarose beads alone (Be), and
lane 5 shows a control IP with mouse IgG (IgG). B: The blot from
A was stripped and re-probed for the presence of PP2A with an
antibody directed against the catalytic subunit of PP2A. C: Immu-
noprecipitation of total p38 using SAK7 followed by immunodetec-
tion of PP2A. Lane 1 shows proteins present in the whole cell lysate
(Wcl) following immune capture of p38. Lane 2 shows the SAK7
antibody control (Ab) and lanes 3^5 show immunoprecipitates of
p38 under resting (0 min) and collagen-stimulated conditions (2 min
and 8 min). Blots shown are representative of at least four similar
experiments.
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cytoskeletal proteins [19]. Similar considerations may apply to
PTP1B and PTP1C [29]. To investigate whether occupancy of
KIIbL3 played a role in p38 phosphorylation and its subse-
quent dephosphorylation in collagen-stimulated platelets, we
employed the KIIbL3 antagonist GR144053F with normal
platelets, and also used KIIbL3-de¢cient platelets from a
Glanzmann’s thrombasthenic patient. Fig. 4A and B show
immunoblots of normal platelets treated with collagen and
CRP-XL respectively. Preincubation with GR144053F had
no e¡ect on the rise in p38 phosphorylation stimulated by
either ligand, measured densitometrically. Decline in phos-
phorylation was still obvious in platelets stimulated with col-
lagen for 8 min. Regardless of the presence of GR144053F,
p38 phosphorylation showed a 35% fall in IOD between 2 and
8 min in the presence of GR144053F, compared with a 37%
fall in control levels. Fibrinogen binding to KIIbL3 was not
necessary for the onset of p38 phosphorylation, its increase
with time, nor its subsequent dephosphorylation, when treated
with collagen or CRP-XL. The use of Glanzmann’s throm-
basthenic platelets supported this conclusion. The curve in
Fig. 4C is similar to that in Fig. 1D. Once again, p38 phos-
phorylation in collagen-stimulated platelets peaked by 90 s
and signi¢cantly declined by 480 s (P6 0.02), whereas with
CRP-XL-stimulated platelets, p38 phosphorylation remained
at a high level (P=0.99).
4. Discussion
We have previously demonstrated that collagen and CRP-
XL can activate p38 MAPK in human platelets [1]. Here, as
others have suggested, we show that the e¡ect of collagen
di¡ers from that of the GpVI-speci¢c ligand, CRP-XL [30].
Both ligands caused rapid onset of p38 phosphorylation,
which peaked between 90 and 120 s. However, in the case
of collagen, but not CRP-XL, p38 phosphorylation levels
fell by almost 50% after 480 s (Fig. 1). These data suggest
that collagen can regulate p38 MAPK dephosphorylation
through receptors other than GpVI, although these remain
to be identi¢ed.
We report here both a functional and a physical association
between p38 and PP2A. The use of the selective PP2A inhib-
itors, fostriecin and OA, reveals that PP2A is responsible for
p38 dephosphorylation in platelets (Fig. 2A and B). Further,
the presence of PP2A in immunoprecipitates of phospho-p38
(Fig. 3B) together with the greater selectivity of fostriecin,
provides strong support for PP2A directly regulating platelet
p38 MAPK activity. To the best of our knowledge, this is the
¢rst report to demonstrate a physical association between
PP2A and p38. The greater amount of PP2A detected at
2 min compared with either 0 or 8 min of stimulation indi-
cates that PP2A interacts more avidly with the phosphorylat-
ed form of the kinase, as hardly any PP2A was detected under
resting conditions (Fig. 3C). The same phenomenon was
found with PP2C, which exclusively bound to the phosphor-
ylated form of p38 and implies a common mode of binding to
p38, by type II protein phosphatases [18].
PP2A is known to inhibit p38 activity in vitro [17]. Similar
experiments support such a role for PP2A in the rat tumor cell
line 9L RBT and in both human skin ¢broblasts and NIH
3T3 cells [31,32], where the use of OA similarly led to an
increase of p38 activity. Together with these reports, our
data suggest that there may be a widespread role for PP2A
in terminating signaling through p38 MAPK. It has recently
been reported that PTPase HePTP in T cells [33] can dephos-
phorylate p38 MAPK, which provides a precedent for a
PTPase acting in concert with PP2A in this process. Our
own results with platelets treated with the general PTPase
inhibitor PAO support this concept, as p38 phosphorylation
was also markedly increased under these conditions (Fig. 2C).
Thus, tyrosine and serine/threonine phosphatases act together
to maintain p38 MAPK predominantly in the non-phosphor-
ylated form seen in resting platelets, and later dephosphory-
late p38 subsequent to signaling through collagen.
Both kinase and phosphatase activity appear to be consti-
tutive in the resting platelet, with the phosphorylated and
basal forms of p38 existing in dynamic equilibrium, since pre-
incubation with OA in the absence of ligand shifted the bal-
ance towards increased p38 phosphorylation. Basal phospha-
tase activity may also contribute to the kinetic pro¢le of p38
activation by collagen, since the 30 s lag preceding the rise in
p38 phosphorylation (Fig. 1D) was abolished in the presence
of OA (Fig. 2A). The decline in control phospho-p38 levels
between 90 and 480 s (Fig. 1D) suggests a relatively slow
increase in PP2A activity after platelet activation by collagen
¢bers.
Fig. 4. p38 phosphorylation and subsequent dephosphorylation oc-
curs independently of integrin KIIbL3. Normal platelets preincu-
bated with GR144053F (2 WM) for 20 min were activated by colla-
gen 50 Wg/ml (A) and CRP-XL 25 Wg/ml (B) for the indicated
times. C: Glanzmann’s platelets were stimulated with collagen (F)
or CRP-XL (R) and phospho-p38 levels as well as whole p38 levels
were measured densitometrically and IOD values were normalized
to account for total p38 levels.
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Experiments using KIIbL3-de¢cient platelets demonstrate
that regulation of p38 MAPK phosphorylation and its sub-
sequent dephosphorylation are independent of the platelet ¢-
brinogen receptor and platelet aggregation (Fig. 4C). These
data were con¢rmed by applying an KIIbL3-speci¢c antago-
nist, GR144053F, to normal platelets, which was without ef-
fect on p38 phosphorylation (Fig. 4A and B. These lines of
argument suggest that, in this respect, p38 appears to di¡er
from the related MAPKs ERK2 and JNK1 whose dephos-
phorylation has been reported to involve KIIbL3 occupancy
in thrombin-stimulated platelets [34].
p38 is considered to be the protein involved with actin
remodeling via its downstream target HSP27 [10], which
may account for its involvement in the platelet aggregation
process [1]. A possible role for platelet p38 may be to mediate
reorganization of the cytoskeleton and formation of signaling
complexes, required for the morphological changes during
aggregation. Cytoskeletal changes which lead to blebbing
[35] and platelet microparticle generation also require the ac-
tivation of p38 MAPK [2]. Protein tyrosine dephosphoryla-
tion is reported to play an integral role in microvesiculation
[28], and perhaps p38 dephosphorylation represents one target
for such activity. Further work will be needed to identify the
PTPase, which jointly acts with PP2A to achieve complete
dephosphorylation of p38 MAPK.
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